Sean P. Nolan's Net Worth
$11.2 Million
Who is Sean P. Nolan?
Sean P. Nolan has an estimated net worth of $11.2 Million. This is based on reported shares across multiple companies, which include Ventas, Inc., Taysha Gene Therapies, Inc., Social Capital Suvretta Holdings Corp. II, Neoleukin Therapeutics, Inc., AveXis, Inc., and INTERMUNE INC.
SEC CIK
Sean P. Nolan's CIK is 0001569926
Past Insider Trading and Trends
2014 was Sean P. Nolan's most active year for acquiring shares with 10 total transactions. Sean P. Nolan's most active month to acquire stocks was the month of April. 2014 was Sean P. Nolan's most active year for disposing of shares, totalling 23 transactions. Sean P. Nolan's most active month to dispose stocks was the month of May. 2023 saw Sean P. Nolan paying a total of $574,990.65 for 448,279 shares, this is the most they've acquired in one year. In 2014 Sean P. Nolan cashed out on 409,000 shares for a total of $8,298,614.71, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Ventas, Inc. (VTR) Snapshot price: $45.08
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +27.85% | 3.83K |
$45.63 | $174,991.05 | 17.6K |
May 16
| |||
Form 4
| +28.53% | 3.06K |
$57.25 | $174,956.00 | 13.77K |
Apr 27
| |||
Form 4
| +41.80% | 3.16K |
—
|
—
| 10.71K |
May 25
| |||
Form 4
| +254.53% | 5.42K |
—
|
—
| 7.55K |
May 18
| |||
Form 4
|
∞
| 2.13K |
$67.03 | $142,840.93 | 2.13K |
Jul 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Taysha Gene Therapies, Inc. (TSHA) Snapshot price: $1.66
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +101,255.38% | 1.18M |
—
|
—
| 1.19M |
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 14
| |||
Form 4
| +40.73% | 444.44K |
$0.90 | $399,999.60 | 1.54M |
Aug 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
∞
| 1.17K |
$22.35 | $26,149.50 | 1.17K |
May 20
| |||
Form 4
|
∞
| 1.09M |
—
|
—
| 1.09M |
Sep 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Social Capital Suvretta Holdings Corp. II No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Neoleukin Therapeutics, Inc. (NLTX) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AveXis, Inc. No price found
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -11.00K |
—
|
—
|
0
|
May 15
| |||
Form 4
|
∞
| 11K |
—
|
—
| 11K |
Mar 13
| |||
Form 4
|
—
|
0
|
$72.71 | -$1,135,257.00 |
0
|
Scheduled
|
Mar 7
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||